Clinical trials: Oral Anticoagulant
Medication Adherence, Atrial Fibrillation (AF)
SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
SNAP AF-52 is an ambidirectional observational registry conducted in family health centers (primary care) across Ordu, Türkiye, enrolling adults ≥65 years with a pre-existing diagnosis of atrial fibrillation.
- Conditions
- Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)
- Trial name
- SNAP AF-52 (NCT07242326)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Kotyora Family Medicine Health Management and Education Association
Solid Tumor, Cancer, Lung
Exploratory Drug Interaction Study Between SMIs and DOACs
The main objective of this study is to investigate the effect of small molecule inhibitors (SMIs), used in targeted therapy for tumours, on direct oral anticoagulants (DOACs).
- Trial name
- NCT05732350
- Where
- 2 sites in Netherlands
- Volunteers
- 37 people
- Sponsor
- Maastricht University Medical Center
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Atrial Fibrillation
Pleotropic Effect of New Oral Anticoagulants
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel.
- Trial name
- NCT02544932
- Testing
- dabigatran, ribaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Kyunghee University Medical Center
Atrial Fibrillation Patients With Intermediate Stroke Risk
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Atrial fibrillation (AF) increases the risk of stroke, and oral anticoagulation is strongly recommended for patients at high thromboembolic risk.
- Trial name
- NCT04437654
- Testing
- Anticoagulation group(DOAC group)
- Where
- South Korea
- Volunteers
- 1,803 people
- Sponsor
- Yonsei University
Atrial Fibrillation
Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation
Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing prevalence AF. The purpose of paroxysmal AF processing is to control outbreaks from these pulmonary veins, medicated way (antiarrhythmic)…
- Trial name
- NACO-VP (NCT02814955)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Caen
Clot Formation and Platelet Aggregation in Point of Care Testing
Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study
The purpose of this study is determine whether point of care coagulation testing is able to map the anticoagulatory effects of new oral anticoagulants dabigatran and rivaroxaban.
- Trial name
- NCT01704053
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Bleeding Post Cardiac Surgery, Indication for Anticoagulation
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with…
- Trial name
- DANCE (NCT04284839)
- Testing
- DOAC, VKA
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 3,500 people
- Sponsor
- Population Health Research Institute
Anticoagulation
Accessibility to New Drugs Versus SOC in Sweden
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment.
- Trial name
- NCT03684395
- Testing
- DOACs: Rivaroxaban, Dabigatran, Apixaban, Standard of care (Warfarin)
- Where
- Sweden
- Volunteers
- 68,056 people
- Sponsor
- Bayer
Antiphospholipid Syndrome, Venous Thromboembolism
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome
- Conditions
- Antiphospholipid Syndrome, Venous Thromboembolism, Arterial Thromboembolism, Major Bleed
- Trial name
- NCT05195372
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Pulmonary Arterial Hypertension
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50…
- Trial name
- HEMA-HTP (NCT02800941)
- Testing
- Oral anticoagulant treatment
- Where
- 4 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Stroke
Study of the Follow-up of Stroke Treated With Anticoagulants
Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap).
- Trial name
- AOD (NCT03292575)
- Testing
- Anticoagulants
- Where
- France
- Volunteers
- 441 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Atrial Fibrillation, Venous Thromboembolism
Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry
Among patients who are receiving long-term anticoagulant therapy, whether with a direct oral anticoagulant (DOAC) or vitamin K antagonist (VKA), approximately 3-5% who require treatment interruption for a surgery will do so in an…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease
- Trial name
- PAUSE-ER (NCT04195113)
- Where
- 3 sites in Canada
- Volunteers
- 242 people
- Sponsor
- McMaster University
Hypercoagulable States
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
Retrospective, cohort study chart review in patients with hypercoagulable states.
- Trial name
- NCT04565977
- Testing
- Observational
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Methodist Health System
Direct Oral Anticoagulant, Hemmorhage
Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly
This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.
- Conditions
- Direct Oral Anticoagulant, Hemmorhage, Elderly, Muscle Mass
- Trial name
- SARCORRHAGED (NCT07173075)
- Testing
- impedancemetry
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Subdural Hematoma, Atrial Fibrillation (AF)
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural…
- Trial name
- RELACS (NCT06696079)
- Testing
- Early Resumption of Oral Anticoagulation Therapy, Late Resumption of Oral Anticoagulation Therapy
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 332 people
- Sponsor
- Rahul Raj
Novel Oral Anticoagulants, NOACs
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT03161496
- Testing
- detection of genotype
- Where
- 17 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Cui Yimin
Oncologic Diseases, Coagulation Defect
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
- Conditions
- Oncologic Diseases, Coagulation Defect, Pain Management
- Trial name
- NCT07384013
- Testing
- metamizole
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rambam Health Care Campus
AOD Prescription
Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence
The use of direct oral anticoagulants (AODs) in the prevention and treatment of thromboembolic diseases is increasing, with a favorable benefit/risk balance and improved quality of life for patients.
- Trial name
- Hemorrag-IR (NCT06739603)
- Testing
- pharmaceutical analysis
- Volunteers
- 1,920 people
- Sponsor
- Université de Reims Champagne-Ardenne